Trump’s 100% Generic Drug Tariff Threat Puts India’s $9.7 Billion US Pharma Exports at Risk
Summarized by AI; it may make mistakes. Check important info
Summarized by AI; it may make mistakes. Check important info
US President Donald Trump’s plan to impose steep tariffs on imported generic medicines could have major implications for India, one of the largest suppliers of generic drugs to the American market.
Under the timeline announced by Trump, generic medicines imported into the US will continue to attract zero tariffs for two years from August 1, 2026. Imports would then face a 100% tariff for one year, followed by a 200% duty.
Trump said the phased tariff plan was aimed at encouraging pharmaceutical companies to shift production to the United States.
Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which the TARIFF will be raised to 100% for a one year period of time, and 200% thereafter.
— Donald Trump
Why India Is in Focus
India is a major supplier of generic medicines to the US and is widely known as the “pharmacy of the world”. Indian-made generic drugs account for nearly 40% of generic prescriptions in the US by volume.
India exported pharmaceuticals worth around $9.7 billion to the US in financial year 2024-25, accounting for nearly 38% of its total global pharmaceutical exports, according to a report by the Global Trade Research Initiative.
Indian drugmakers, including Cipla, Sun Pharmaceutical Industries and Dr Reddy’s Laboratories, are among the major suppliers to the US market.
Two-Year Window for Indian Drugmakers
Trump’s proposed tariff structure would give Indian pharmaceutical companies a two-year window to establish manufacturing facilities in the US before higher duties come into effect.
However, several details remain unclear, including whether companies that begin constructing plants during the two-year period would qualify for exemptions or whether manufacturing would have to begin before the 100% tariff is imposed.
The impact could depend on how the US administration implements the policy and whether exemptions are provided for specific medicines, companies or manufacturing arrangements.
Trade Pact Could Become Important
The proposed tariff plan also comes amid a recent trade understanding between India and the US that included negotiated outcomes related to generic pharmaceuticals and their ingredients.
This could become significant for Indian drugmakers if the proposed tariffs are implemented, although it remains unclear how the new announcement would interact with existing trade commitments.
US Pushes for Domestic Production
Trump said the tariff policy was intended to “reshore” generic pharmaceutical production to the US and penalise companies that choose not to build manufacturing facilities there.
“The objective of this Policy is to protect the people of the United States,” he said.
For India, the key question now is whether the proposed tariffs will force pharmaceutical companies to increase their manufacturing presence in the US, absorb higher costs, or seek exemptions under existing trade arrangements.
